Page last updated: 2024-11-13

1229u91

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1229U91: a selective neuropeptide Y-Y1 receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24868178
CHEMBL ID4648150
MeSH IDM0255746

Synonyms (8)

Synonym
NCGC00167147-01
1229u91
158859-98-4
AKOS024456630
l-tyrosinamide,l-isoleucyl-l-a-glutamyl-l-prolyl-3-amino-l-alanyl-l-tyrosyl-l-arginyl-l-leucyl-l-arginyl-, bimol. (24'),(2'4)-dilactam
bdbm50542833
CHEMBL4648150 ,
PD079050

Research Excerpts

Overview

1229U91 was found to be a potent and selective NPY antagonist.

ExcerptReferenceRelevance
"1229U91 was found to be a potent and selective NPY antagonist."( A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats.
Fukami, T; Fukuroda, T; Ihara, M; Ishihara, A; Kanatani, A; Tanaka, T, 1998
)
1.3

Treatment

ExcerptReferenceRelevance
"Pretreatment with 1229U91 did not modify glucose profiles between +2 and +9 h after multiple dosing with NPH, but prevented recovery from hypoglycemia at +12 h."( Effects of intracerebroventricular administration of the NPY-Y1 receptor antagonist, 1229U91, on hyperphagic and glycemic responses to acute and chronic intermediate insulin-induced hypoglycemia in female rats.
Briski, KP; Nedungadi, TP, 2010
)
0.91

Dosage Studied

ExcerptRelevanceReference
" [Leu31 Pro34]-rNPY (agonist potency: Y1 > Y5 > Y4 = y6) and human pancreatic polypeptide (hPP) produced flatter dose-response curves, suggesting partial agonism at the receptor(s)."( Characterisation of the neuropeptide Y receptor that mediates feeding in the rat: a role for the Y5 receptor?
Arch, JR; Buckingham, RE; Haynes, AC; McClue, S; Wilson, S, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency1.41250.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuropeptide Y receptor type 4Homo sapiens (human)Ki0.00040.00040.00040.0004AID1660937
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayNeuropeptide Y receptor type 4Homo sapiens (human)
neuropeptide signaling pathwayNeuropeptide Y receptor type 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
pancreatic polypeptide receptor activityNeuropeptide Y receptor type 4Homo sapiens (human)
G protein-coupled receptor activityNeuropeptide Y receptor type 4Homo sapiens (human)
peptide hormone bindingNeuropeptide Y receptor type 4Homo sapiens (human)
neuropeptide bindingNeuropeptide Y receptor type 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneNeuropeptide Y receptor type 4Homo sapiens (human)
membraneNeuropeptide Y receptor type 4Homo sapiens (human)
neuron projectionNeuropeptide Y receptor type 4Homo sapiens (human)
plasma membraneNeuropeptide Y receptor type 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1660937Displacement of [3H]UR-KK200 from human Y4 receptor expressed in CHO cells co-expressing Gqi5-mtAEQ measured after 90 mins by scintillation counting analysis
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (59)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's23 (38.98)18.2507
2000's26 (44.07)29.6817
2010's8 (13.56)24.3611
2020's2 (3.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.15 (24.57)
Research Supply Index4.09 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other59 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]